C12N 2795/00032
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2795/00032 (Use of virus as therapeutic agent, other than vaccine) appears on 149 US grants and 281 published applications in this corpus.
Search patents in C12N- Granted patents
- 149
- Published applications
- 281
- Assignees
- 114
- Inventors
- 416
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 1 | 0 |
| 2004 | 1 | 5 |
| 2005 | 1 | 4 |
| 2006 | 0 | 3 |
| 2007 | 1 | 5 |
| 2008 | 2 | 7 |
| 2009 | 3 | 4 |
| 2010 | 2 | 9 |
| 2011 | 1 | 3 |
| 2012 | 4 | 11 |
| 2013 | 7 | 7 |
| 2014 | 4 | 9 |
| 2015 | 7 | 15 |
| 2016 | 12 | 23 |
| 2017 | 18 | 18 |
| 2018 | 9 | 20 |
| 2019 | 12 | 22 |
| 2020 | 14 | 17 |
| 2021 | 10 | 20 |
| 2022 | 7 | 14 |
| 2023 | 13 | 18 |
| 2024 | 5 | 24 |
| 2025 | 8 | 10 |
| 2026 | 5 | 12 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method for reducing the population of at least one intestinal and/or gastrointestinal bacteria species comprising bacteriophages, and bacteriophages and the use thereof14 Jul 2026US 12,678,468 B2
- Bacteriophages producing heterologous bacteriocins7 Jul 2026US 12,673,078 B2ETH Zurich
- Altering microbial populations and modifying microbiota6 Jan 2026US 12,514,867 B2SNIPR Technologies Limited
- Altering microbial populations and modifying microbiota6 Jan 2026US 12,514,869 B2SNIPR Technologies Limited
- Propagator cells and methods for propagating phage, in particular for delivering CRISPR-Cas components via probiotic organisms6 Jan 2026US 12,516,297 B2SNIPR Technologies Limited
- Bacteriophage vb_sbrt-pbovineb21 having lytic activity and biofilm control activity against streptococcus bovis/streptococcus equinus complex and lactic acid-producing bacteria1 Oct 2026US 2026/0297541 A1Gachon University of Industry-Academic Cooperation Foundation
- Method of production of modified phage and method of treatment using same24 Sep 2026US 2026/0286316 A1Aushealth Corporate Pty Ltd
- A combination of succinate consuming microbiotas10 Sep 2026US 2026/0265680 A1
- Bacteriophage, composition, and method for controlling bacteria of the genus salmonella27 Aug 2026US 2026/0248865 A1Kaneka Corporation
- Bacteriophages, lytic agents for salmonella species, compositions, and method for controlling salmonella species27 Aug 2026US 2026/0248866 A1Kaneka Corporation
Most cited
By later US patents
- Probiotic recolonisation therapy240US 8,460,648 B22013
- Probiotic recolonisation therapy117US 9,408,872 B2Crestovo LLC · 2016
- Compositions for probiotic recolonisation therapy76US 9,040,036 B22015
- Compositions and methods for probiotic recolonization therapies76US 9,050,358 B22015
- Probiotic recolonisation therapy75US 9,572,841 B2Crestovo LLC · 2017